Dr. Neil J. Campbell Is Appointed Marizyme CEO, President and Member of Board of Directors

Xenter, Inc. Appoints 4 Industry Leaders to Board of Directors; Closes $12M Series A

Xenter’s first product, which the company will announce shortly, is a medical device that not only combines the function of multiple existing devices but will also revolutionize the field of interventional medicine by producing valuable Physical Intelligence™ data and enabling advanced Artificial Intelligence solutions, leading to improved patient outcomes while reducing the cost, complexity and invasiveness of cardiac procedures.

Indivumed Partners with Oslo University Hospital to Advance Cancer Research

By scanning high-resolution images of haematoxylin and eosin-stained tumor section slides for all IndivuType cases, Indivumed will be able to leverage an entirely new dimension of data in the coming months.

Harold Hill Joins NeuX Technologies as Director of Corporate Accounts

Harold Hill is a retired Special Forces Medic, serving 26 years, and led the medical department for a Special Missions Unit within the United States Special Operations Command

November 6, 2020

Dr. Neil J. Campbell has been appointed Marizyme CEO and President and member of their board of directors. The news was announced today.

Dr. Neil J. Campbell has more than 35 years of successful experience with public and private companies in the life sciences, medical, health tech, nanotechnology, artificial intelligence, and high-performance computing technologies, including with IGEN International (now Roche), Celera Genomics, and Abbott Laboratories. He also has prior institutional investment experience as a partner in venture capital and operating partner and industry advisor in private equity.

James Sapirstein, Marizyme’s Executive Chairman, who also served as Interim CEO, commented, “Neil is a strong leader who will take Marizyme to the next level by advancing the company’s clinical programs and develop strategies and execution to unlock shareholder value.  His extensive executive experience in the life sciences and medical industries, as well as his investment background, will guide Marizyme as the company grows its life science assets and seeks to elevate its financial position.”

“I am very excited to join the Marizyme team,” said Dr. Campbell. “Marizyme has great potential in the pipeline of products in development and the early success of products like DuraGraft®, which has been shown to reduce graft failure in bypass surgery and significantly reduce major adverse cardiac events such as repeat revascularization and myocardial infarction.”

Dr. Campbell currently serves as Chairman of Mosaigen®, a commercial development company, and RespaRx™, a medical device company. Previously, Dr. Campbell served as Chairman, CEO, and founder of Celios®, a respiratory device company that was acquired by a private investment group. Prior to founding Celios, Dr. Campbell was Co-founder, President and CEO of Helomics, a personalized healthcare company focused on next-generation therapeutics and diagnostics.

Dr. Campbell has held senior executive positions at SuperNova Diagnostics, EntreMed Pharmaceuticals, Life Technologies, IGEN International (now Roche), Celera Genomics, and Abbott Laboratories. He has also held academic positions at Johns Hopkins University and Medical Institutes, Hong Kong University of Science and Tech, University of Liverpool (UK), University of Baltimore and Duquesne University in Pittsburgh, PA.

Dr. Campbell earned his B.S. from Norwich University; his M.A. and M.B.A. from Webster University; and his Doctorate from the University of Liverpool in the UK.

spot_img

DON'T MISS

Subscribe to Medical Device News Magazine

Related Articles